|
ZDHHC4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.79199988181722E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.03149752365084E-11 |
| Normal-vs-Stage2 |
1.339610E-01 |
| Normal-vs-Stage3 |
6.06020011950648E-10 |
| Normal-vs-Stage4 |
2.02620031863887E-10 |
| Stage1-vs-Stage2 |
1.619620E-03 |
| Stage1-vs-Stage3 |
2.521600E-01 |
| Stage1-vs-Stage4 |
2.099500E-02 |
| Stage2-vs-Stage3 |
1.433290E-04 |
| Stage2-vs-Stage4 |
4.42700000000684E-05 |
| Stage3-vs-Stage4 |
2.286200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.22239951073323E-10 |
| Normal-vs-AfricanAmerican |
4.43309999997865E-06 |
| Normal-vs-Asian |
1.79019999935193E-08 |
| Caucasian-vs-AfricanAmerican |
7.363200E-01 |
| Caucasian-vs-Asian |
7.094800E-01 |
| AfricanAmerican-vs-Asian |
5.819600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.38379974146119E-10 |
| Normal-vs-Female |
2.67279998134029E-09 |
| Male-vs-Female |
2.296600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.88626891883814E-12 |
| Normal-vs-Age(41-60Yrs) |
1.84240000034031E-07 |
| Normal-vs-Age(61-80Yrs) |
2.73309999965221E-07 |
| Normal-vs-Age(81-100Yrs) |
9.762700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.347700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.443200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.899000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.473400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.944000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.572200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.72217999999669E-05 |
| Classical-VS-Follicular |
2.076000E-02 |
| Classical-VS-Other |
4.009600E-01 |
| Classical-VS-Normal |
4.31480406959395E-11 |
| Tall-VS-Follicular |
3.98119999966973E-07 |
| Tall-VS-Other |
6.363600E-01 |
| Tall-VS-Normal |
2.99760216648792E-15 |
| Follicular-VS-Other |
1.804800E-01 |
| Follicular-VS-Normal |
1.017900E-03 |
| Other-VS-Normal |
9.844100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44970000001987E-06 |
| Normal-vs-N1 |
3.84559051269662E-12 |
| N0-vs-N1 |
6.29119999999705E-05 |
|
|
